Current Report Filing (8-k)
December 04 2018 - 6:08AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of
Report (Date of earliest event reported): November 30,
2018
GENETHERA, INC.
(Exact
name of registrant as specified in its charter)
Nevada
|
000-27237
|
65-0622463
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File
Number)
|
(I.R.S.
Employer
Identification
No.)
|
6860 Broadway, Denver, CO
|
80221
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
(303) 955-0190
|
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy t
he filing
obligation of the registrant under any of the following
provisions.
|
|
☐
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
|
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (
17 CFR
240.14d-2(b))
|
|
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
Item 1.01 Entry into a Material Definitive
Agreement.
GENETHERA INC.
COMPLETES THIRD MILESTONE OF THEIR “MILESTONE INVESTMENT
AGREEMENT” WITH FOGT, LLC
On
November 30
th
2018, GeneThera
Inc. completed the third milestone as described in Exhibit A of the
Milestone Investment Agreement. The Completion of this milestone
enables the Company to receive a payment of $1,200,000 under the
Terms of the Agreement.
Item 9.01 Financial Statements and
Exhibits.
Exhibit
Number
|
Description
|
|
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this Current Report on Form 8-K to be signed on its
behalf by the undersigned hereunto duly authorized.
|
GeneThera,
Inc.,
a Nevada
Corporation
|
|
|
|
|
|
|
By:
|
/s/
Antonio
Milici
|
|
|
|
Antonio Milici,
CEO
|
|
Date: December 4, 2018
GeneThera (CE) (USOTC:GTHR)
Historical Stock Chart
From Jun 2024 to Jul 2024
GeneThera (CE) (USOTC:GTHR)
Historical Stock Chart
From Jul 2023 to Jul 2024